

Contact:

Karen A. Donato, Ph.D.
Executive Vice President, Sales and Marketing
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

***Improved Optimization and Development of
Ion Channels for Cell-Based Assays
MaxCyte Webinar with Case Studies from BioFocus***

Gaithersburg, MD, January 26, 2010 –MaxCyte, Inc., the leader in scalable, high performance cell loading systems, will host case study discussions with industry experts demonstrating how the MaxCyte® STX™ Scalable Transfection System improves transfection of cells with ion channels for cell-based assays for drug discovery screening. The technical discussion will be held by webinar on Thursday, January 28, 2010 from 11:00-Noon EST.

Dr. James Brady, Director of Technical Applications at MaxCyte, will demonstrate how the MaxCyte STX technology can be used to quickly and efficiently develop and optimize cell-based assays that scale seamlessly from the bench to the high throughput screening line.

Dr. Andrew Southan, Director of Ion Channel Biology at BioFocus, will discuss the importance of ion channel assays in drug discovery screening programs and how the MaxCyte STX can accelerate assay development.

Dr. Gary Clark, Group Leader of Ion Channel Biology at BioFocus, will describe experiments conducted at BioFocus using the MaxCyte STX technology for ion channel assays. Dr. Clark will provide technical details on the performance of cells transfected with the Kv1.5 potassium ion channel and assessed using the IonWorks® Quattro™.

“We are delighted to present these case studies in ion channel transfection from users of the MaxCyte STX, and validation of our technology by such renowned industry experts as Dr. Southan and Dr. Clark of BioFocus,” says Douglas Doerfler, President and CEO of MaxCyte. “The ability of the MaxCyte STX to transfect cells with ion channels and other hard-to-transfect targets is proving to be a valuable tool for pharmaceutical companies to accelerate the screening of compound libraries for drug candidate selection.”

To register for the free webinar, visit www.maxcyte.com and click on the registration link. A recording of the webinar will be available on the MaxCyte website after the event.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte® STX™ Scalable Transfection System enables rapid development and consistent production of cell lines and primary cells

for use in HTS and HCS cell based assays for ion channels, GPCRs, and other targets. The MaxCyte STX transfects primary cells, cell lines, and stem cells with high loading efficiency, cell viability, reproducibility, and consistency, with Seamlessly Scalable™ results from the bench to high throughput screens. **For more information, www.maxcyte.com**

About BioFocus

BioFocus aims to expand its partners' drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As the service division of Galapagos, BioFocus has 250 employees in four countries worldwide.

###